Cambium Bio Secures A$2.4 Million Strategic Investment
Filed with ASX · · 5 pages · English
Sydney, Australia; 20 January 2026: Cambium Bio Limited (ASX:CMB) (“Cambium Bio”, “Cambium” or “Company”), a clinical-stage regenerative medicine company focused on ophthalmology and tissue repair, is pleased to announce that it has received a firm commitment from Zheng Yang Biomedical Technology Co., Ltd. (ZYBT) to invest A$2.4 million through a placement of 4,363,637 new fully-paid ordinary shar
Story so far
Earlier from Cambium Bio
- Cambium Bio Signs Strategic MoU with Benta SAS
- Cambium Bio Signs US$2.0M plus Licensing Deal
- FY25 Appendix 4E and Annual Report
- Placement Participant Update
- Cambium Bio Raises A$2.12 million
Later from Cambium Bio
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Year Report and Accounts
- FDA Confirms Single Pivotal Trial Pathway for Elate Ocular
- Cambium Bio Raises A$1.0 Million via Placement
- Updated Securities Trading Policy
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio